Drug profile · INN
insulin lispro protamine recombinant
HUMALOG MIX 50/50 KWIKPEN
insulin lispro protamine recombinant (HUMALOG MIX 50/50 KWIKPEN) is a insulin receptor agonist. Route of administration: injection. Current US regulatory status: approved.
Drug details — insulin lispro protamine recombinant
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 1
- Data quality
- 0.84
Quick answer
insulin lispro protamine recombinant (HUMALOG MIX 50/50 KWIKPEN) is a insulin receptor agonist. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Insulin receptor agonist
Primary target: Insulin receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is insulin lispro protamine recombinant?
insulin lispro protamine recombinant (HUMALOG MIX 50/50 KWIKPEN) is a insulin receptor agonist. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for insulin lispro protamine recombinant?
HUMALOG MIX 50/50 KWIKPEN is a marketed brand name for insulin lispro protamine recombinant. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of insulin lispro protamine recombinant?
insulin lispro protamine recombinant has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.